Stay updated on STK-012 in Solid Tumors with Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the STK-012 in Solid Tumors with Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the STK-012 in Solid Tumors with Pembrolizumab Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the history. The funding-lapse notice and the earlier revision note (v3.4.1) were removed.
    Difference
    0.7%
    Check dated 2026-02-11T02:17:34.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a government funding notice and a new revision entry (v3.4.1) to the history, and removed the previous revision entry (v3.4.0).
    Difference
    0.7%
    Check dated 2026-02-04T00:28:16.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page history now includes a 'Show glossary' option, green highlights for additions, red highlights for deletions, and an updated revision indicator to v3.4.0.
    Difference
    0.9%
    Check dated 2026-01-27T23:08:06.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The history now includes a new version entry (v3.3.4) and removes v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T00:48:37.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Added a new Revision: v3.3.3 entry; removed HHS Vulnerability Disclosure and Revision: v3.3.2 from the history. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-12-23T07:58:00.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors was replaced with a broader 'Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers (SYNERGY-101)'. The update adds or updates sections including Contacts/Locations, Eligibility, Outcome Measures, Arms and Interventions, Study Design, Conditions, Study Description, Oversight, Study Status, and Study Identification.
    Difference
    1%
    Check dated 2025-12-01T15:11:16.000Z thumbnail image

Stay in the know with updates to STK-012 in Solid Tumors with Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the STK-012 in Solid Tumors with Pembrolizumab Clinical Trial page.